Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) ExtendedRelease Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
Inaugural NYC Event Raises Nearly Half a Million Dollars to Support Narcolepsy Research, Awareness and Education